SODIAP
Board
3 directors, 1 in day-to-day management, 1 auditor, last change in May 2026ALEXO BV
Chair of the board and director, permanent representative Olivier Delaere
chair of the board appointed by deed of 25-11-2022
director since 22-12-2020
also on the board of 45 other companies
listed in the 2025 annual accounts, filed on 13-05-2026
GODEPHAR BV
Director and managing director, permanent representative GODERIS Tom Karel Rogier
director since 22-12-2020
managing director appointed by deed of 12-11-2021
term without a fixed end
listed in the 2025 annual accounts, filed on 13-05-2026
Statutory auditor
appointed by deed of 09-12-2022
listed in the 2025 annual accounts, filed on 13-05-2026
Permanent representatives 3
Mandates through the years
8 names, the dashed line is todayALEXO
Chair of the board
Chair of the board
GODEPHAR
Director, Managing director
Director, Managing director
BV KST Pharma
Director
Director
Moore Audit
Statutory auditor
Statutory auditor
ARISTO
Director
Director
COENE Frank Philip Cornelius
Director
Director
GODERIS Tom Karel Rogier
Director
Director
VAN NUETEN Eric
Director
Director
LeadershipBoardEarliermandate already running before its first mentionend not dated
Mandates as a list
- ALEXO
- Director, from 22-12-2020 to 18-05-2026
- Chair of the board, appointed by deed of 25-11-2022, still in office
- GODEPHAR
- Director, from 22-12-2020 to date
- Managing director, appointed by deed of 12-11-2021, still in office
- BV KST Pharma
- Director, appointed by deed of 05-08-2026, still in office
- Moore Audit
- Statutory auditor, since before 31-12-2021
- ARISTO
- Director, from 22-12-2020 to 31-08-2022
- Chair, appointed by deed of 12-11-2021, ended, last mentioned on 12-11-2021
- COENE Frank Philip Cornelius
- Director, until 22-02-2021
- GODERIS Tom Karel Rogier
- Director, until 22-02-2021
- VAN NUETEN Eric
- Director, until 22-02-2021
Control
Parent
Equity €103.6m
Profit €4.4m in 2025 (profit €4.2m in 2024)
Checked score 80
Source: accounts FEBELCO 2025
100%
This company
SODIAP
Equity €33.0m
Profit €411,580 in 2025
Further up the chainPHARMACIE BIA 100%
Capital
- Capital
- €11,105,318.25
- Shares
- 28,500 in the 2025 annual accounts
- Contribution per share
- €390
- Equity per share
- €1,159 in 2025
- Source
- deed of 11-05-2023
Owners through the years
as the annual accounts name themOwners as a list
Source: parent in its own accounts, lists of holdings in the owners' accounts
Articles of association
deed of 22-02-2021 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Second Wednesday of May at 09:30
Capital transactions
Shareholders according to the deeds
Stated in the deed
deed of 11-05-2023 ↗
- Febelco CV 28,500 shares · 100%
Capital over time
- 11-05-2023 Capital stated in the deed · €11,105,318.25 · 28,500 shares
- 22-02-2021 Converted to unavailable equity